JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M201507200 on March 6, 2002

J. Biol. Chem., Vol. 277, Issue 21, 18973-18978, May 24, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/21/18973    most recent
M201507200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karthikeyan, S.
Right arrow Articles by Ladias, J. A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karthikeyan, S.
Right arrow Articles by Ladias, J. A. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Structural Determinants of the Na+/H+ Exchanger Regulatory Factor Interaction with the beta 2 Adrenergic and Platelet-derived Growth Factor Receptors*

Subramanian Karthikeyan, Teli Leung, and John A. A. LadiasDagger

From the Molecular Medicine Laboratory and Macromolecular Crystallography Unit, Division of Experimental Medicine, Harvard Institutes of Medicine, Harvard Medical School, Boston, Massachusetts 02115

Received for publication, February 13, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The Na+/H+ exchanger regulatory factor (NHERF) binds through its PDZ1 domain to the carboxyl-terminal sequences NDSLL and EDSFL of the beta 2 adrenergic receptor (beta 2AR) and platelet-derived growth factor receptor, respectively, and plays a critical role in the membrane localization and physiological regulation of these receptors. The crystal structures of the human NHERF PDZ1 domain bound to the sequences NDSLL and EDSFL have been determined at 1.9- and 2.2-Å resolution, respectively. The beta 2AR and platelet-derived growth factor receptor ligands insert into the PDZ1 binding pocket by a beta -sheet augmentation process and are stabilized by largely similar networks of hydrogen bonds and hydrophobic contacts. In the PDZ1-beta 2AR complex, the side chain of asparagine at position -4 in the beta 2AR peptide forms two additional hydrogen bonds with Gly30 of PDZ1, which contribute to the higher affinity of this interaction. Remarkably, both complexes are further stabilized by hydrophobic interactions involving the side chains of the penultimate amino acids of the peptide ligands, whereas the PDZ1 residues Asn22 and Glu43 undergo conformational changes to accommodate these side chains. These results provide structural insights into the mechanisms by which different side chains at the position -1 of peptide ligands interact with PDZ domains and contribute to the affinity of the PDZ-ligand interaction.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The Na+/H+ exchanger regulatory factor (NHERF)1 is a cytoplasmic phosphoprotein originally identified as an essential cofactor for the inhibition of the Na+/H+ exchanger 3 by the cAMP-dependent protein kinase A in the renal brush-border membrane (1). NHERF, also known as ezrin/radixin/moesin-binding phosphoprotein 50 or EBP50 (2), contains two PDZ (PSD-95/Discs-large/ZO-1) domains that bind to carboxyl-terminal sequences of membrane proteins and an ezrin/radixin/moesin-binding domain that interacts with the cortical actin cytoskeleton (2, 3). Through these interactions, NHERF plays central roles in the membrane targeting, trafficking, and sorting of several ion channels, transmembrane receptors, and signaling proteins (reviewed in Ref. 4).

Previous studies have shown that the amino-terminal PDZ domain of NHERF, referred to as PDZ1, binds with high affinity to the carboxyl termini of the cystic fibrosis transmembrane conductance regulator (CFTR), beta 2 adrenergic receptor (beta 2AR), and platelet-derived growth factor receptor (PDGFR) (5-7). The PDZ1-mediated interaction of NHERF with the carboxyl-terminal motif DTRL of CFTR is essential for the functional expression in the apical plasma membrane and gating of the CFTR channel, and the mutations that destroy this motif result in abnormal apical polarization of CFTR and defective vectorial chloride transport (8, 9). Likewise, the binding of the NHERF PDZ1 domain to the beta 2AR carboxyl-terminal sequence NDSLL is essential for the beta 2AR-mediated regulation of Na+/H+ exchange (6). This interaction also mediates the sorting of internalized beta 2AR between degradative endocytic pathways and plasma membrane recycling; the truncation of the beta 2AR carboxyl terminus prevents NHERF PDZ1 binding and leads to lysosomal degradation of the receptor (10). Importantly, the phosphorylation of the serine within the beta 2AR sequence NDSLL (Ser411 in the full-length receptor) by the G-protein-coupled receptor kinase-5 inhibits the NHERF PDZ1-beta 2AR interaction and regulates beta 2AR endocytic sorting (10). In addition, the NHERF PDZ1 interacts with the motif EDSFL, which is present at the carboxyl termini of PDGFR forms A and B, and potentiates PDGFR autophosphorylation and extracellular signal-induced kinase activation (5, 7). Notably, a single mutation of the PDGFR carboxyl-terminal leucine to alanine abolishes binding to NHERF PDZ1 and impairs the receptor activity, demonstrating the critical role of this interaction in PDGFR function (7).

PDZ domains are protein-protein interaction modules that participate in the assembly of membrane receptors, ion channels, and other signaling molecules into specific signal transduction complexes (11, 12). These domains bind to short carboxyl-terminal sequence motifs and were initially grouped into two classes based on target sequence specificity. Class I domains bind to peptides with the consensus sequence (S/T)X(V/I/L) (X denoting any amino acid), whereas class II domains recognize the motif (F/Y)X(F/V/A) (13). However, other PDZ domains have ligand sequence specificities that do not fall into these two categories, suggesting the existence of more PDZ classes (11, 12). The PDZ-fold comprises a six-stranded antiparallel beta -barrel capped by two alpha -helices (14-22). Peptide ligands interact with PDZ domains by a beta -sheet augmentation process in which the peptide adds an antiparallel beta -strand to the preexisting PDZ beta -sheet (23).

The specificity of the PDZ-ligand interaction is achieved by the residues at positions -3, -2, and 0 of the peptide (position 0 referring to the carboxyl-terminal residue) (11, 12). By contrast, initial biochemical and structural studies indicated that the residue at position -1 of the peptide ligand plays no role in the interaction with PDZ domains (13, 14, 16). However, more recent studies demonstrated a strong preference of PDZ domains for specific side chains at position -1, suggesting an important role of these side chains in the PDZ-ligand interaction (17, 24, 25). In the case of NHERF, affinity selection experiments showed that PDZ1 selected almost exclusively ligands with arginine at position -1 from random peptides (25), and mutagenesis of the penultimate arginine to other residues decreased the affinity of the PDZ1-ligand interaction (5). A structural explanation for this preference was provided by the crystal structure of the human NHERF PDZ1 domain complexed with the CFTR carboxyl-terminal sequence QDTRL (22). In this structure, the guanidino group of arginine at position -1 of the CFTR peptide forms two salt bridges and two hydrogen bonds with PDZ1 residues Glu43 and Asn22, respectively, thus contributing to the affinity of the PDZ1-ligand interaction. This finding led to the hypothesis that PDZ residues corresponding to the hNHERF PDZ1 Asn22 and Glu43 may play a more general role in the interaction with the penultimate residues of the peptide ligands (22).

Here, we describe the crystal structures of hNHERF PDZ1 bound to the carboxyl-terminal sequences NDSLL and EDSFL of beta 2AR and PDGFR, respectively. The structures provide new insights into the mechanisms by which hydrophobic side chains at position -1 interact with this domain, contributing to the affinity of the interaction, and reveal the conformational changes that the PDZ1 residues Asn22 and Glu43 undergo to accommodate these side chains.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Protein Purification and Crystallization-- A DNA fragment encoding the human NHERF PDZ1 domain (residues 11-94) and having the carboxyl-terminal extension N95DSLL99 that corresponds to residues 409-413 of human beta 2AR was amplified using the polymerase chain reaction and cloned in the vector pGEX-2TJL (22). A similar strategy was used to generate the hNHERF PDZ1 domain (residues 11-94) having the carboxyl-terminal extension E95DSFL99 that corresponds to residues 1085-1089 and 1102-1106 of human PDGFRA and PDGFRB, respectively. The resulting chimeric PDZ1-beta 2AR and PDZ1-PDGFR domains were expressed in Escherichia coli BL21 (DE3) cells as glutathione S-transferase fusion proteins purified using glutathione-Sepharose 4B resin and released from the glutathione S-transferase moiety by digestion with thrombin as described previously (21). PDZ1-beta 2AR protein (19 mg/ml) was crystallized using the sitting drop vapor diffusion method in 0.1 M citric acid, pH 4.24, and 1 M lithium chloride at 20 °C, whereas PDZ1-PDGFR (18 mg/ml) was crystallized in 0.1 M sodium acetate, pH 4.6, 2 M sodium chloride at 20 °C. Both crystals were cryoprotected in 20% (v/v) glycerol for 3 min and flash-frozen in a stream of liquid nitrogen. Diffraction data sets were collected at 115 K using CuKalpha radiation from a Rigaku RU-300 generator and an R-AXIS IV-imaging plate detector. The data were processed and scaled using the programs DENZO and SCALEPACK (26) (Table I). Both crystals belong to space group P3121 with one molecule in the asymmetric unit and unit cell parameters: a = b = 50.37 Å, c = 66.63 Å (for PDZ1-beta 2AR) and a = b = 50.07 Å, c = 66.68 Å (for PDZ1-PDGFR).

Structure Determination and Refinement-- Both structures were solved by molecular replacement using the program MOLREP (27) and the hNHERF PDZ1 (Protein Data Bank code 1g9o) as the search model. For PDZ1-beta 2AR, the model was truncated by removing the last six carboxyl-terminal residues. The rotation function search in the resolution range from 20.0 to 3.0 Å produced a clear solution with a peak height of 6.53sigma above the mean. The translation function indicated that the correct space group was P3121 with a correlation coefficient of 47.6% and an R-factor of 47.3%. For the structure determination of PDZ1-PDGFR, a polyalanine model of hNHERF PDZ1 was used for molecular replacement in order to remove any model bias. The rotation function in the resolution range from 20.0 to 3.0 Å produced a solution with a peak height of 6.31sigma above the mean, and the translation function indicated that the space group was also P3121 with a correlation coefficient of 55.6% and an R-factor of 42.7%. Models were built using the program O (28) and were refined by the maximum likelihood method using REFMAC5 (29). Both structures are well ordered with the exception of the loop region spanning residues 31-35, which is disordered. The crystallized proteins also contained at their amino termini the vector-derived residues GSSRM from which only methionine is ordered and included in both models, whereas arginine is partially ordered and represented as a glycine in the PDZ1-PDGFR model.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Overview of the PDZ1-beta 2AR and PDZ1-PDGFR Structures-- To determine the crystal structures of the hNHERF PDZ1 domain bound to the beta 2AR and PDGFR carboxyl-terminal ligands, we adopted a crystallization strategy similar to that used in the hNHERF PDZ1-CFTR structural analysis (22). In this approach, we crystallized the hNHERF PDZ1 domain (residues 11-94) fused to either the beta 2AR carboxyl-terminal sequence N95DSLL99 or the PDGFR carboxyl-terminal motif E95DSFL99 (Fig. 1A). As in the case of hNHERF PDZ1-CFTR, the hNHERF PDZ1-beta 2AR and hNHERF PDZ1-PDGFR crystal structures produced infinite head-to-tail polymers of PDZ1 molecules along the z axis with the carboxyl-terminal pentapeptide extension of one chimeric PDZ1 molecule serving as a ligand for a neighboring PDZ1 (Fig. 1B). Both crystal structures were solved by molecular replacement using the hNHERF PDZ1 structure (21) as the search model. The PDZ1-beta 2AR structure was refined to an Rcryst of 17.1% and an Rfree of 18.6%, whereas the PDZ1-PDGFR model was refined to an Rcryst of 22.2% and an Rfree of 26.3% (Table I). An evaluation of the stereochemistry of the PDZ1-beta 2AR structure using PROCHECK (30) showed that 89% of the residues are in the most favored region and 9.6% in the additional allowed regions. One residue (Ala81) is disordered and located in the disallowed region of the Ramachandran plot. A similar analysis of the PDZ1-PDGFR model placed 87.8% of the residues in the most favored and 12.2% in the additional allowed regions.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 1.   Structure of the hNHERF PDZ1 domain bound to the beta 2AR and PDGFR carboxyl-terminal sequences. A, sequences of the chimeric hNHERF PDZ1-beta 2AR (PDZ1B) and PDZ1-PDGFR (PDZ1P) proteins used in this study. Amino acid residues belonging to the beta 2AR and PDGFR carboxyl termini are shaded in yellow. Secondary structure elements are indicated at the top. B, stereo view of the hNHERF PDZ1-beta 2AR crystal packing. Each carboxyl terminus serves as a ligand for a neighboring PDZ1 molecule. C, ribbon diagram of the hNHERF PDZ1 domain bound to the beta 2AR carboxyl-terminal sequence NDSLL. A weighted 2Fobs - Fcalc electron density map calculated at 1.9-Å resolution and contoured at 1.0sigma is superimposed on the beta 2AR ligand. D, ribbon diagram of the hNHERF PDZ1 domain bound to the PDGFR carboxyl-terminal sequence EDSFL. A weighted 2Fobs - Fcalc electron density map calculated at 2.2-Å resolution and contoured at 1.0sigma is superimposed on the PDGFR ligand. The figure was made using MOLSCRIPT (35), BOBSCRIPT (36), Raster3D (37), and POV-Ray (www.povray.org).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Statistics of structure determination and refinement

The hNHERF PDZ1 core domain consists of six beta -strands (beta 1-beta 6) and two alpha -helices (alpha 1 and alpha 2) (Fig. 1, A, C, and D). The beta 2AR and PDGFR carboxyl-terminal sequences NDSLL and EDSFL, respectively, insert into the PDZ1 binding pocket as additional beta -strands (beta 7) antiparallel to beta 2 and extend the beta -sheet of PDZ1. In this arrangement, the invading pentapeptide ligands are highly ordered as indicated by the high quality electron density maps (Fig. 1, C and D) and average B factors of 13.5 Å2 for beta 2AR and 30.7 Å2 for PDGFR.

Specificity Determinants of the hNHERF PDZ1 Interaction with beta 2AR and PDGFR-- The stabilization of the PDZ1-beta 2AR and PDZ1-PDGFR interactions is achieved through networks of hydrogen bonds and hydrophobic interactions, which to a large extent are similar in the two protein-peptide complexes. The side chains of residues Leu 0, Ser -2, and Asp -3, which are common in both ligands, are engaged in numerous interactions with PDZ1 residues, consistent with biochemical evidence on the central role of these residues in the specificity and affinity of the NHERF PDZ1 interaction with beta 2AR and PDGFR (5-10). Specifically, in both PDZ1-beta 2AR and PDZ1-PDGFR structures, the side chain and carboxylate group of Leu 0 enter into a deep cavity formed by Tyr24, Gly25, Phe26, Leu28, Val76, and Ile79 residues. In this position, the carboxyl oxygen of Leu 0 hydrogen bonds with the amide nitrogens of Gly25 and Phe26, whereas the carbonyl oxygen of Leu 0 hydrogen bonds directly with the amide nitrogen of Tyr24 (Fig. 2, A-D). The isobutyl group of Leu 0 is stabilized by hydrophobic interactions with PDZ residues that are largely similar in both structures (Fig. 2, C and D). Moreover, in both complexes the amide nitrogen and carbonyl oxygen atoms of Ser -2 hydrogen bond with the carbonyl oxygen and amide nitrogen of Leu28, respectively, whereas the Ogamma 1 atom of Ser -2 hydrogen bonds with the Nepsilon 2 atom of the conserved His72. These interactions corroborate previous studies that demonstrated the critical role of a serine or threonine at position -2 of the ligand and a histidine at the beginning of the alpha 2 helix for the specificity of class I PDZ-peptide interactions (5, 6, 10, 12, 13). In the case of the beta 2AR ligand, the phosphorylation of Ser -2 by G-protein-coupled receptor kinase-5 has been shown to abrogate the interaction with NHERF PDZ1 and play an important role in the regulation of beta 2AR endocytic sorting (10). Based on the current PDZ1-beta 2AR structure, it could be predicted that the added phosphoryl group on the Ser -2 would sterically clash with the imidazole group of His72, dislodging the main chain of the peptide away from the binding pocket and disrupting several hydrogen bonds that stabilize the PDZ-peptide beta -sheet.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 2.   PDZ1 interaction with the beta 2AR and PDGFR carboxyl termini. A and B, stereo images of the hNHERF PDZ1 binding pocket bound to the beta 2AR (A) and PDGFR (B) carboxyl-terminal ligands. Carbon, oxygen, and nitrogen atoms are shown in black, red, and blue, respectively. Water molecules are depicted as green spheres, and hydrogen bonds are shown as dashed lines. C and D, two-dimensional representations of the interactions observed between the hNHERF PDZ1 residues (orange) and beta 2AR (C) or PDGFR (D) peptide ligands (purple). Dashed lines denote hydrogen bonds, and numbers indicate hydrogen bond lengths in Å. Hydrophobic interactions are shown as arcs with radial spokes. C and D were generated using LIGPLOT (38). E, superposition of the hNHERF PDZ1 bound to CFTR (yellow), beta 2AR (blue), and PDGFR (pink) peptide ligands. For clarity, the beta 2 strand and alpha 2 helix of the PDZ1 domain are shown as ribbon diagrams, and only the Calpha traces are shown for the remaining PDZ1 main chain. Side chains of the peptide ligands and the PDZ1 residues Asn22 and Glu43 are shown as ball-and-stick models.

As observed previously in the hNHERF PDZ1-CFTR structure (22), in both PDZ1-beta 2AR and PDZ1-PDGFR complexes the Odelta 1 atom of Asp -3 hydrogen bonds with Ndelta 1 of His27, the Odelta 2 atom of Asp -3 forms a salt bridge with Neta 1 of Arg40, and the carbonyl oxygen of the residue at position -4 hydrogen bonds with the amide nitrogen of Gly30 (Fig. 2, A-D). However, in the PDZ1-beta 2AR structure the Odelta 1 and Ndelta 2 atoms of Asn -4 make two additional hydrogen bonds with the amide nitrogen and carbonyl oxygen of Gly30, respectively (Fig. 2, A and C), that contribute to the affinity of this interaction.

Role of the Penultimate Residue in the PDZ-Peptide Interaction-- As mentioned above, in the hNHERF PDZ1-CFTR structure, the guanidino group of Arg -1 forms two salt bridges with Oepsilon 2 of Glu43 and two hydrogen bonds with the carbonyl oxygen of Asn22 (22). This unexpected finding suggests that the residue -1 of the peptide plays an important role in the affinity of the PDZ-ligand interaction. It also raises the question of whether nonpolar side chains at position -1 of peptide ligands, such as the large hydrophobic side chains of the penultimate residues of beta 2AR and PDGFR, interact with the hNHERF PDZ1 or are disordered facing toward the solution. The present structures clearly demonstrate that both the isobutyl group of Leu -1 and the phenolic ring of Phe -1 of the beta 2AR and PDGFR ligands, respectively, are well ordered (Fig. 1, C and D) and engage in hydrophobic interactions with PDZ1 residues. Specifically, the Cdelta 1 atom of the beta 2AR Leu -1 contacts the Cdelta 2 atom of His27, whereas the Cdelta 1 and Cbeta atoms of the PDGFR Phe -1 contact the Cdelta 2 and Cepsilon 1 atoms of His27, respectively (Fig. 2, A and B). These results provide compelling structural evidence for the importance of the penultimate ligand residue in the affinity of the PDZ-peptide interaction. In agreement with this conclusion, the recent crystal structure of the InaD PDZ1 complexed with the carboxyl-terminal sequence of NorpA revealed the presence of an intermolecular disulfide bond formed between Cys -1 of the peptide ligand and a cysteine residue of the PDZ domain (31).

Another notable feature in the present structures is that the carbonyl oxygen atoms of the penultimate residues of both beta 2AR and PDGFR ligands make direct hydrogen bonds with the Neta 2 atom of Arg80 (Fig. 2, A and B). In this respect, the PDZ1-beta 2AR and PDZ1-PDGFR structures differ from that of PDZ1-CFTR where the carbonyl oxygen of Arg -1 does not hydrogen bond directly with Arg80 (22). Moreover, the carbonyl oxygen of Leu 0 interacts indirectly with the Nepsilon atom of Arg80 through two ordered water molecules in the PDZ1-beta 2AR and PDZ1-CFTR structures but not in the PDZ1-PDGFR complex. These findings demonstrate that the networks of hydrogen bonds and ordered water molecules participating in hydrogen bonding between the PDZ domain and the peptide differ among various ligands bound to the same PDZ domain.

Structural Basis for the PDZ Interaction with Different Penultimate Residues-- The ability of the hNHERF PDZ1 domain to interact with different side chains at position -1 of the peptide ligand raises the question of whether PDZ residues around the binding pocket undergo conformational changes to accommodate different ligands. The superposition of the hNHERF PDZ1 domains bound to the beta 2AR, PDGFR, and CFTR peptides reveals the structural differences among the three complexes and provides insights into the mechanisms underlying PDZ-ligand recognition. The three liganded hNHERF PDZ1 structures are very similar with overall root- mean-square deviations ranging from 0.53 to 0.88 Å (Fig. 2E). Larger differences in the backbone positions are observed in the beta 2-beta 3 and alpha 2-beta 6 loops with root-mean-square deviation ranges of 1.13-1.98 and 1.08-1.59 Å, respectively. The main chains of the three peptide ligands and the side chains of residues at positions 0, -2, and -3 are superimposed extremely well, whereas large deviations are observed in the orientations of the side chains at position -4 (Fig. 2E). To a large extent, the side chains of Phe -1 and Leu -1 follow a path similar to that of the aliphatic portion of the Arg -1 side chain, facing toward the PDZ residues Asn22 and Glu43. Notably, the side chains of these two PDZ residues exhibit the largest conformational changes seen in all three complexes. In the PDZ1-beta 2AR structure, the side chain of Asn22 is oriented toward the isobutyl group of Leu -1, whereas in the PDZ1-PDGFR and PDZ1-CFTR complexes, the amide group is rotated away from the longer side chains of Phe -1 and Arg -1 because of steric effects (Fig. 2E). Remarkably, the Glu43 side chain occupies three different positions for optimal ligand interaction. These findings indicate that the conformational changes of Asn22 and Glu43 underlie the hNHERF PDZ1 flexibility to accommodate ligands with penultimate side chains of different hydrophobicity and polarity and suggest similar roles for the corresponding residues of other PDZ domains.

Perspective-- This work provides the structural basis for the interaction of beta 2AR and PDGFR with hNHERF PDZ1 and expands our insights into the molecular mechanisms underlying peptide recognition by class I PDZ domains. The observed differences in the hNHERF PDZ1 interaction with the CFTR, beta 2AR, and PDGFR ligands also indicate that although PDZ domains are structurally simple protein interaction modules sharing the same fold, more biochemical and structural studies are needed to derive the structural principles governing the selection of their target peptides.

From a clinical standpoint, because of the central roles of beta 2AR and PDGFR in human physiology and pathology, the structural determinants of the hNHERF PDZ1 interaction with these receptors may have important applications in molecular medicine. For example, this information may be used for the design of a new class of specific inhibitors of these receptors, which would act by disrupting the hNHERF PDZ1-receptor interaction and block the functional localization in plasma membrane and activity of these receptors. It was previously shown that beta 2AR agonists induce conformational changes in the receptor that promote a direct physical association of its carboxyl terminus to the hNHERF PDZ1 (6). Therefore, small molecules that would block specifically the hNHERF PDZ1-beta 2AR interaction could act as beta 2AR antagonists. Likewise, the inhibitors of the hNHERF PDZ1-PDGFR interaction could be useful in reducing the mitogenic activity of this receptor in tumor cells. In this context, it is of particular interest to note that the hNHERF gene expression is rapidly activated by estrogen in estrogen receptor-positive breast cancer cells (32), and estrogen receptor levels correlate closely with hNHERF expression in breast carcinomas (33), raising the intriguing possibility that hNHERF may play an important role in breast cancer development through potentiation of the PDGFR mitogenic activity (7). Moreover, it was recently shown that PDGFRA is significantly up-regulated in metastatic medulloblastoma and enhances the migration properties of medulloblastoma cells, suggesting that strategies aiming at inhibiting PDGFRA function could constitute novel therapeutic approaches against medulloblastoma (34). Therefore, it is conceivable that the hNHERF PDZ1-PDGFR atomic structure may provide the framework for the design of small molecules that would block this interaction and decrease the PDGFR-proliferative activity in cancer cells.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and the structure factors (code 1gq4 and 1gq5) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

Dagger Established Investigator of the American Heart Association. To whom correspondence should be addressed: Molecular Medicine Laboratory and Macromolecular Crystallography Unit, Harvard Institutes of Medicine, Rm. 354, 4 Blackfan Circle, Boston, MA 02115. Tel.: 617-667-0064; Fax: 617-975-5241; E-mail: jladias@caregroup.harvard.edu.

Published, JBC Papers in Press, March 6, 2002, DOI 10.1074/jbc.M201507200

    ABBREVIATIONS

The abbreviations used are: NHERF, Na+/H+ exchanger regulatory factor 1; hNHERF, human NHERF; beta 2AR, beta 2 adrenergic receptor; CFTR, cystic fibrosis transmembrane conductance regulator; PDZ, PSD-95/Discs-large/ZO-1 homology; PDGFR, platelet-derived growth factor receptor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Weinman, E. J., Steplock, D., Wang, Y., and Shenolikar, S. (1995) J. Clin. Invest. 95, 2143-2149[Medline] [Order article via Infotrieve]
2. Reczek, D., Berryman, M., and Bretscher, A. (1997) J. Cell Biol. 139, 169-179[Abstract/Free Full Text]
3. Murthy, A., Gonzalez-Agosti, C., Cordero, E., Pinney, D., Candia, C., Solomon, F., Gusella, J., and Ramesh, V. (1998) J. Biol. Chem. 273, 1273-1276[Abstract/Free Full Text]
4. Shenolikar, S., and Weinman, E. J. (2001) Am. J. Physiol. 280, F389-F395
5. Hall, R. A., Ostedgaard, L. S., Premont, R. T., Blitzer, J. T., Rahman, N., Welsh, M. J., and Lefkowitz, R. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8496-8501[Abstract/Free Full Text]
6. Hall, R. A., Premont, R. T., Chow, C. W., Blitzer, J. T., Pitcher, J. A., Claing, A., Stoffel, R. H., Barak, L. S., Shenolikar, S., Weinman, E. J., Grinstein, S., and Lefkowitz, R. J. (1998) Nature 392, 626-630[CrossRef][Medline] [Order article via Infotrieve]
7. Maudsley, S., Zamah, A. M., Rahman, N., Blitzer, J. T., Luttrell, L. M., Lefkowitz, R. J., and Hall, R. A. (2000) Mol. Cell. Biol. 20, 8352-8363[Abstract/Free Full Text]
8. Moyer, B. D., Duhaime, M., Shaw, C., Denton, J., Reynolds, D., Karlson, K. H., Pfeiffer, J., Wang, S., Mickle, J. E., Milewski, M., Cutting, G. R., Guggino, W. B., Li, M., and Stanton, B. A. (2000) J. Biol. Chem. 275, 27069-27074[Abstract/Free Full Text]
9. Raghuram, V., Mak, D. D., and Foskett, J. K. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 1300-1305[Abstract/Free Full Text]
10. Cao, T. T., Deacon, H. W., Reczek, D., Bretscher, A., and von Zastrow, M. (1999) Nature 401, 286-290[CrossRef][Medline] [Order article via Infotrieve]
11. Hung, A. Y., and Sheng, M. (2002) J. Biol. Chem. 277, 5699-5702[Free Full Text]
12. Harris, B. Z., and Lim, W. A. (2001) J. Cell Sci. 114, 3219-3231[Medline] [Order article via Infotrieve]
13. Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997) Science 275, 73-77[Abstract/Free Full Text]
14. Doyle, D. A., Lee, A., Lewis, J., Kim, E., Sheng, M., and MacKinnon, R. (1996) Cell 85, 1067-1076[CrossRef][Medline] [Order article via Infotrieve]
15. Morais Cabral, J. H., Petosa, C., Sutcliffe, M. J., Raza, S., Byron, O., Poy, F., Marfatia, S. M., Chishti, A. H., and Liddington, R. C. (1996) Nature 382, 649-652[CrossRef][Medline] [Order article via Infotrieve]
16. Daniels, D. L., Cohen, A. R., Anderson, J. M., and Brünger, A. T. (1998) Nat. Struct. Biol. 5, 317-325[CrossRef][Medline] [Order article via Infotrieve]
17. Schultz, J., Hoffmuller, U., Krause, G., Ashurst, J., Macias, M. J., Schmieder, P., Schneider-Mergener, J., and Oschkinat, H. (1998) Nat. Struct. Biol. 5, 19-24[CrossRef][Medline] [Order article via Infotrieve]
18. Tochio, H., Zhang, Q., Mandal, P., Li, M., and Zhang, M. (1999) Nat. Struct. Biol. 6, 417-421[CrossRef][Medline] [Order article via Infotrieve]
19. Kozlov, G., Gehring, K., and Ekiel, I. (2000) Biochemistry 39, 2572-2580[CrossRef][Medline] [Order article via Infotrieve]
20. Hillier, B. J., Christopherson, K. S., Prehoda, K. E., Bredt, D. S., and Lim, W. A. (1999) Science 284, 812-815[Abstract/Free Full Text]
21. Karthikeyan, S., Leung, T., Birrane, G., Webster, G., and Ladias, J. A. A. (2001) J. Mol. Biol. 308, 963-973[CrossRef][Medline] [Order article via Infotrieve]
22. Karthikeyan, S., Leung, T., and Ladias, J. A. A. (2001) J. Biol. Chem. 276, 19683-19686[Abstract/Free Full Text]
23. Harrison, S. C. (1996) Cell 86, 341-343[CrossRef][Medline] [Order article via Infotrieve]
24. Fuh, G., Pisabarro, M. T., Li, Y., Quan, C., Lasky, L. A., and Sidhu, S. S. (2000) J. Biol. Chem. 275, 21486-21491[Abstract/Free Full Text]
25. Wang, S., Raab, R. W., Schatz, P. J., Guggino, W. B., and Li, M. (1998) FEBS Lett. 427, 103-108[CrossRef][Medline] [Order article via Infotrieve]
26. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol. 276, 307-326
27. Vagin, A. A., and Teplyakov, A. (1997) J. Appl. Crystallogr. 30, 1022-1025[CrossRef]
28. Jones, T. A., Zou, J. Y., Cowan, S., and Kjeldgaard, M. (1991) Acta Crystallogr. Sec. A 47, 110-119[CrossRef]
29. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Acta Crystallogr. Sec. D 53, 240-255[CrossRef][Medline] [Order article via Infotrieve]
30. Laskowski, R. J., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) J. Appl. Crystallogr. 26, 283-291[CrossRef]
31. Kimple, M. E., Siderovski, D. P., and Sondek, J. (2001) EMBO J. 20, 4414-4422[CrossRef][Medline] [Order article via Infotrieve]
32. Ediger, T. R., Kraus, W. L., Weinman, E. J., and Katzenellenbogen, B. S. (1999) Endocrinology 140, 2976-2982[Abstract/Free Full Text]
33. Stemmer-Rachamimov, A. O., Wiederhold, T., Nielsen, G. P., James, M., Pinney-Michalowski, D., Roy, J. E., Cohen, W. A., Ramesh, V., and Louis, D. N. (2001) Am. J. Pathol. 158, 57-62[Abstract/Free Full Text]
34. MacDonald, T. J., Brown, K. M., LaFleur, B., Peterson, K., Lawlor, C., Chen, Y., Packer, R. J., Cogen, P., and Stephan, D. A. (2001) Nat. Genet. 29, 143-152[CrossRef][Medline] [Order article via Infotrieve]
35. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef]
36. Esnouf, R. M. (1997) J. Mol. Graph. Model. 15, 132-134[CrossRef][Medline] [Order article via Infotrieve]
37. Merritt, E. A., and Murphy, M. E. P. (1994) Acta Crystallogr. Sec. D 50, 869-873[CrossRef][Medline] [Order article via Infotrieve]
38. Wallace, A. C., Laskowski, R. A., and Thornton, J. M. (1995) Protein Eng. 8, 127-134[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Protein Sci.Home page
S. T. Runyon, Y. Zhang, B. A. Appleton, S. L. Sazinsky, P. Wu, B. Pan, C. Wiesmann, N. J. Skelton, and S. S. Sidhu
Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3
Protein Sci., November 1, 2007; 16(11): 2454 - 2471.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Li, P. I. Poulikakos, Z. Dai, J. R. Testa, D. J. E. Callaway, and Z. Bu
Protein Kinase C Phosphorylation Disrupts Na+/H+ Exchanger Regulatory Factor 1 Autoinhibition and Promotes Cystic Fibrosis Transmembrane Conductance Regulator Macromolecular Assembly
J. Biol. Chem., September 14, 2007; 282(37): 27086 - 27099.
[Abstract] [Full Text] [PDF]


Home page
Protein Sci.Home page
Y. Zhang, B. A. Appleton, P. Wu, C. Wiesmann, and S. S. Sidhu
Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain
Protein Sci., August 1, 2007; 16(8): 1738 - 1750.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. A. Appleton, Y. Zhang, P. Wu, J. P. Yin, W. Hunziker, N. J. Skelton, S. S. Sidhu, and C. Wiesmann
Comparative Structural Analysis of the Erbin PDZ Domain and the First PDZ Domain of ZO-1: INSIGHTS INTO DETERMINANTS OF PDZ DOMAIN SPECIFICITY
J. Biol. Chem., August 4, 2006; 281(31): 22312 - 22320.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Zhang, S. Yeh, B. A. Appleton, H. A. Held, P. J. Kausalya, D. C. Y. Phua, W. Lee Wong, L. A. Lasky, C. Wiesmann, W. Hunziker, et al.
Convergent and Divergent Ligand Specificity among PDZ Domains of the LAP and Zonula Occludens (ZO) Families
J. Biol. Chem., August 4, 2006; 281(31): 22299 - 22311.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Li, Z. Dai, D. Jana, D. J. E. Callaway, and Z. Bu
Ezrin Controls the Macromolecular Complexes Formed between an Adapter Protein Na+/H+ Exchanger Regulatory Factor and the Cystic Fibrosis Transmembrane Conductance Regulator
J. Biol. Chem., November 11, 2005; 280(45): 37634 - 37643.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Zhou, Y. Xu, Y. Yang, A. Huang, J. Wu, and Y. Shi
Solution Structure of AF-6 PDZ Domain and Its Interaction with the C-terminal Peptides from Neurexin and Bcr
J. Biol. Chem., April 8, 2005; 280(14): 13841 - 13847.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
S. Shenolikar, J. W. Voltz, R. Cunningham, and E. J. Weinman
Regulation of Ion Transport by the NHERF Family of PDZ Proteins
Physiology, December 1, 2004; 19(6): 362 - 369.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. L. Hildreth, J.-H. Wu, L. S. Barak, S. T. Exum, L. K. Kim, K. Peppel, and N. J. Freedman
Phosphorylation of the Platelet-derived Growth Factor Receptor-{beta} by G Protein-coupled Receptor Kinase-2 Reduces Receptor Signaling and Interaction with the Na+/H+ Exchanger Regulatory Factor
J. Biol. Chem., October 1, 2004; 279(40): 41775 - 41782.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Yoo, T. P. Flagg, O. Olsen, V. Raghuram, J. K. Foskett, and P. A. Welling
Assembly and Trafficking of a Multiprotein ROMK (Kir 1.1) Channel Complex by PDZ Interactions
J. Biol. Chem., February 20, 2004; 279(8): 6863 - 6873.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
V. Raghuram, H. Hormuth, and J. K. Foskett
A kinase-regulated mechanism controls CFTR channel gating by disrupting bivalent PDZ domain interactions
PNAS, August 5, 2003; 100(16): 9620 - 9625.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
E. D. Lederer, S. J. Khundmiri, and E. J. Weinman
Role of NHERF-1 in Regulation of the Activity of Na-K ATPase and Sodium-Phosphate Co-transport in Epithelial Cells
J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1711 - 1719.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. Levi
Role of PDZ Domain-Containing Proteins and ERM Proteins in Regulation of Renal Function and Dysfunction
J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1949 - 1951.
[Full Text] [PDF]


Home page
Protein Sci.Home page
A. C. Hamilton, J. Inglese, and M. Ferrer
A PDZ domain-based assay for measuring HIV protease activity: Assay design considerations
Protein Sci., March 1, 2003; 12(3): 458 - 467.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. J. Skelton, M. F. T. Koehler, K. Zobel, W. L. Wong, S. Yeh, M. T. Pisabarro, J. P. Yin, L. A. Lasky, and S. S. Sidhu
Origins of PDZ Domain Ligand Specificity. STRUCTURE DETERMINATION AND MUTAGENESIS OF THE ERBIN PDZ DOMAIN
J. Biol. Chem., February 21, 2003; 278(9): 7645 - 7654.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Birrane, J. Chung, and J. A. A. Ladias
Novel Mode of Ligand Recognition by the Erbin PDZ Domain
J. Biol. Chem., January 10, 2003; 278(3): 1399 - 1402.
[Abstract] [Full Text] [PDF]


This Article